Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA (MRK)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck KGaA May Withdraw Research from Portugal over Debt-Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 08:28am CET

German chemical company Merck KGaA (>> Merck KGaA) may withdraw future investments for research projects in Portugal worth tens of millions of euros unless the government hospitals stick to the agreed-upon debt repayments, German daily newspaper Financial Times Deutschland reports Monday.

Merck Portugal's manager Fritz Sacher told the paper the company's research projects are long-term and require mutual trust as a basis. "The Portuguese government's lacking payment habits undermine this trust," he is quoted as saying.

Portuguese government hospitals owe the pharmaceutical industry a total of more than 1.5 billion euros ($1.84 billion) and companies have to wait nearly 550 days on average until invoices are paid, FTD reports.

Some companies, including Roche Holding AG (ROG.VX), have already halted the sale of medications on credit to highly indebted countries like Portugal, Greece, Spain and Italy until outstanding debts are paid, the paper notes, but for many companies such drastic steps are difficult as they carry responsibility for people's wellbeing.

Withdrawing research projects is a way of putting pressure on the government, as Portugal is an attractive location for research investments, FTD says. "The conditions for certain research and human studies are as good as in the U.S., but it's significantly more cost-effective in Portugal," Sacher told the paper.

Newspaper website: http://www.ftd.de

Write to the Frankfurt Bureau at [email protected]

Stocks mentioned in the article : Merck KGaA
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
11/17 MERCK : Darmstadt, Germany's Massachusetts-based Business Sectors Named 'Top Pla..
11/16 MERCK KGAA : Release according to Article 26, Section 1 of the WpHG [the German ..
11/15 Bayer hires new blood to stem 'Amazon effect' in consumer health
11/15 MERCK : EMD Serono Receives FDA Approval for New GONAL-f RFF Redi-ject Pen
11/13 MERCK : Receives FDA Approval for New GONAL-f® Prefilled Pen
11/13 MERCK : and International Diabetes Federation Partner to Help Address Global Typ..
11/13 MERCK KGAA : Release according to Article 26, Section 1 of the WpHG [the German ..
11/10 MERCK : Darmstadt, Germany, Explores Digital Transformations at Displaying Futur..
11/09 MERCK : Findings in Osteoarthritis Reported from Merck KGaA
11/09 MERCK : Lupus Foundation of America and EMD Serono Launch The ALPHA Project to I..
More news
News from SeekingAlpha
11/13 Orexigen Contrave up 10% on Contrave distribution deal with Merck KGaA for La..
11/13 Merck KGaA ADR 2017 Q3 - Results - Earnings Call Slides
11/09 Merck KGaA (MKGAF) Q3 2017 Results - Earnings Call Transcript
11/09 Merck KGaA reports Q3 results
10/27 JUNIPER PHARMACEUTICALS : A High Risk, High Reward Women's Health Play
Financials (€)
Sales 2017 15 350 M
EBIT 2017 3 282 M
Net income 2017 1 633 M
Debt 2017 9 829 M
Yield 2017 1,39%
P/E ratio 2017 20,83
P/E ratio 2018 20,49
EV / Sales 2017 1,40x
EV / Sales 2018 1,25x
Capitalization 11 704 M
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 109 €
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Michael Fletterich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-8.66%13 796
ABBVIE49.49%149 223
KYOWA HAKKO KIRIN CO LTD33.75%11 130
JAZZ PHARMACEUTICALS PLC22.78%8 026
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD42.96%6 074
CONVATEC GROUP-12.18%5 289